Table 4.
∆ BASMI | ∆ ASDAS-CRP | CRP baseline | IL-6 baseline | IL-17 baseline | TNF-α baseline | ∆ CRP | ∆ IL-6 | ∆ IL-17 | ∆ TNF-α | ||
---|---|---|---|---|---|---|---|---|---|---|---|
∆ BASMI | ρ | 1 | 0.271 | -0.017 | 0.236 | -0.027 | -0.311 | 0.003 | -0.058 | -0.049 | 0.417 |
All (n = 40) | ρ | . | ns | ns | ns | ns | 0.09 | ns | ns | ns | p < 0.05 |
∆ ASDAS-CRP | ρ | 0.271 | 1 | -0.231 | 0.391 | -0.131 | -0.02 | 0.406 | -0.205 | 0.035 | 0.377 |
All (n = 40) | ρ | ns | . | ns | p < 0.05 | ns | ns | p < 0.001 | ns | ns | p < 0.05 |
∆ BASMI | ρ | 1 | 0.774 | -0.596 | 0.441 | -0.230 | -0.477 | -0.098 | -0.213 | 0.010 | 0.563 |
nr-axSpA (n = 18) | ρ | . | p < 0.001 | p < 0.01 | ns | ns | ns | ns | ns | ns | p < 0.05 |
∆ ASDAS-CRP | ρ | 0.774 | 1 | -0.187 | 0.388 | 0.028 | -0.351 | 0.437 | -0.249 | -0.074 | 0.636 |
nr-axSpA (n = 18) | ρ | p < 0.001 | . | ns | ns | ns | ns | p < 0.05 | ns | ns | p < 0.05 |
∆ BASMI | ρ | 1 | 0.007 | 0.233 | 0.099 | 0.217 | -0.143 | 0.123 | 0.158 | -0.110 | 0.273 |
AS (n = 22) | ρ | . | ns | ns | ns | ns | ns | ns | ns | ns | ns |
∆ ASDAS-CRP | ρ | 0.007 | 1 | -0.328 | 0.356 | -0.266 | 0.102 | 0.395 | -0.147 | 0.154 | 0.186 |
AS (n = 22) | ρ | ns | . | ns | ns | ns | ns | p < 0.05 | ns | ns | ns |
Statistical analysis: correlation analyses were performed by Spearman correlation (ρ). Statistical significance was determined as p < 0.05. axSpA axial spondyloarthritis, nr-axSpA non-radiographic axial spondyloarthritis, AS ankylosing spondylitis, ASDAS-CRP AS disease activity score, BASMI Bath AS metrology index, CRP C-reactive protein, IL interleukin, TNF tumour necrosis factor, ∆ changes of the scores/biomarkers values, ns not significant